The DOI matches its OpenAlex record; 104 of the 104 references it cites were found in a registry or an index.
Targeted Therapies for Cancer 2004
Abstract
The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)--and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment--are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer: The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cited by
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Ge, Z., & Liu, S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60048c · Cited by 914
Castano, A. P., Demidova, T. N., & Hamblin, M. R. (2005) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/s1572-1000(05)00030-x · Cited by 767
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Genomic and personalized medicine: foundations and applications
Ginsburg, G. S., & Willard, H. F. (2009) · Translational Research · doi:10.1016/j.trsl.2009.09.005 · Cited by 637
Self-citationHyaluronic acid and its biomedical applications: A review
Dovedytis, M., Liu, Z. J., & Bartlett, S. (2020) · Engineered Regeneration · doi:10.1016/j.engreg.2020.10.001 · Cited by 413
Luong, D., Kesharwani, P., Deshmukh, R., Mohd Amin, M. C. I., Gupta, U., Greish, K., & Iyer, A. K. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.07.015 · Cited by 408
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Agero, A. L. C., Dusza, S. W., Benvenuto-Andrade, C., Busam, K. J., Myskowski, P., & Halpern, A. C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.010 · Cited by 381
Nanoparticles as carriers for drug delivery in cancer
Dadwal, A., Baldi, A., & Kumar Narang, R. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1457039 · Cited by 335
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery
Li, M., Zhao, G., Su, W.-K., & Shuai, Q. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00647 · Cited by 253
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104
Self-citation
Metadata
- Authors
- Ross, J. S., Schenkein, D. P., Pietrusko, R. G., Rolfe, M., Linette, G. P., Stec, J. J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N.
- Venue
- American Journal of Clinical Pathology
- Publisher
- Oxford University Press
- Published
- 2004-01-01
- Volume
- 122
- Issue
- 4
- Pages
- 598-609
- ISSN
- 0002-9173 (ISSN-L)
- OpenAlex
- W2170083676
- Cited by
- 286
- References
- 104
- FWCI
- 26.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.